Takeda Guidance on Novel Coronavirus and Product Supply

Industry News
The following is a letter from Takeda.

 “To the bleeding disorders community, 
As a global pharmaceutical leader, our top priority during the ongoing COVID-19 outbreak is to do all we can to make sure our medicines and services continue to reach the individuals who rely on them, while we protect the health of our employees, those who work alongside them, their families and our communities. 
Based on our current assessment of our global supply chain, we do not foresee any current risk of disruption resulting from the Coronavirus outbreak. Nonetheless, we are continuing to closely monitor the external environment and the situation as it evolves. We will update you as needed. 
Patients and caregivers should feel free to reach out to Takeda’s Hematology Support Center at (888) 229-8379, Monday through Friday from 8:30 a.m. to 8:00 p.m. Eastern Time with any additional questions. For healthcare professionals, please contact Takeda Medical Information at (800) 828-2088.”